In ₹ Crore except Per Share Latest Annual | SYNGENE FY26 | SAILIFE FY26 | DIVISLAB FY26 | WOCKPHARMA FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | ◆ 48.79× | 95.70× | 97.31× | 169.20× | 97.31× -50% | |
| P/B | ◆ 3.20× | 13.57× | 14.89× | 6.81× | 13.57× -76% | |
| EV/EBITDA | ◆ 16.11× | 53.35× | 72.47× | 57.45× | 57.45× -72% | |
| Market Cap | ₹15,471 Cr | ₹33,705 Cr | ₹2.49L Cr | ₹35,962 Cr | ₹35,962 Cr -57% | |
| Growth | ||||||
| Revenue CAGR 3Y | 5.40% | — | ◆ 10.78% | 8.36% | 9.57% -44% | |
| Revenue CAGR 5Y | ◆ 11.35% | — | 8.67% | 4.49% | 6.58% +72% | |
| Net Income CAGR 3Y | -11.98% | — | ◆ 12.09% | — | 12.09% -199% | |
| Revenue YoY (latest Q) | -15.84% | 11.66% | ◆ 27.80% | 25.88% | 25.88% -161% | |
| Net Income YoY (latest Q) | -110.38% | 21.22% | 65.50% | ◆ 199.07% | 65.50% -269% | |
| Profitability | ||||||
| EBITDA Margin | 24.57% | 28.79% | ◆ 32.59% | 19.33% | 28.79% -15% | |
| Net Income Margin | 8.47% | 15.91% | ◆ 24.32% | 5.90% | 15.91% -47% | |
| Return on Common Equity | 6.54% | 14.05% | ◆ 15.32% | 4.03% | 14.05% -53% | |
| Return on Capital Employed | 8.46% | ◆ 16.63% | 16.55% | 6.08% | 16.55% -49% | |
| Return on Assets | 4.49% | 9.62% | ◆ 12.82% | 2.31% | 9.62% -53% | |
| Credit & Quality | ||||||
| Total Debt/Equity | ◆ 0.00× | 0.04× | 0.00× | 0.40× | 0.04× -100% | |
| Interest Coverage | 9.54× | 11.83× | ◆ 129.48× | 2.00× | 11.83× -19% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹3,739 Cr | ₹2,192 Cr | ₹10,560 Cr | ₹3,373 Cr | ₹3,373 Cr +11% | |
| Net Income | ₹317 Cr | ₹349 Cr | ₹2,568 Cr | ₹199 Cr | ₹349 Cr -9% | |
| Total Assets | ₹7,055 Cr | ₹3,626 Cr | ₹20,033 Cr | ₹8,615 Cr | ₹8,615 Cr -18% | |
| EPS | ₹7.87 | ₹16.63 | ₹96.75 | ₹13.12 | ₹16.63 -53% | |
| Book Value per Share | ₹120.11 | ₹117.28 | ₹632.49 | ₹325.99 | ₹325.99 -63% | |